American Journal of PharmacoGenomics

A.H. Maitland-van der Zee

S.T. Turner

G.L. Schwartz

A.B. Chapman

O.H. Klungel

E. Boerwinkle

A multilocus approach to the pharmacogenetics of thiazide diuretics

噻嗪类利尿剂的药物基因组学多基因位点研究

Eating disorders such as anorexia nervosa and bulimia nervosa involve complex and interacting mechanisms. Formal genetic studies suggest that there is a substantial genetic influence for these disorders. Animal models of eating disorders are scarce. Candidate gene studies have initially focused on the serotonergic and other central neurotransmitter systems and on genes involved in body weight regulation. Most of the studies, including meta-analysis, have yielded negative results; only a single positive finding has been replicated independently. Recently, systematic genome-wide scans based on families with two or more individuals with an eating disorder (anorexia nervosa or bulimia nervosa) revealed initial linkage regions on chromosomes 1, 3, and 4 (anorexia nervosa) and 10p (bulimia nervosa). Fine mapping of one of these regions led to the identification of genes where an association with anorexia nervosa was detected. Currently treatment of patients with eating disorders can not rely on results of molecular genetic studies.

Anke Hinney

Susann Friedel

Helmut Remschmidt

Johannes Hebebrand

Am J Pharmacogenomics

Genetic Risk Factors in Eating Disorders

进食障碍的遗传风险因素

Genetic diversity contributes to both disease susceptibility and variability in response to drugs. However, it has proven difficult to isolate genes that underlie common complex disease, and genetic variations that influence clinical responses to drugs remain largely uncovered. The candidate gene approach to uncover genetic variations that contribute to disease susceptibility or variations in response to common drugs has not met expectations. Although the sib-pair linkage approach has certain theoretical advantages in dealing with common/complex disease, success has been slow in coming. Meanwhile family studies including siblings, cousins and second cousins, and studies in well-defined founder populations, have increasingly gained popularity and enabled scientists to map and isolate genes for common complex disease, such as schizophrenia and asthma. The latter method has generated new hope that this approach may also be effective in mapping genes that regulate drug response. Indeed, there is compelling evidence that corticosteroid sensitivity is a mapable trait in patients with asthma. Collectively, these studies support the value of leveraging information available within population-based data systems to map and isolate genes for common complex disease and drug response.

+5d/bs	e+/GRg: Adis International Ltd，uzYam8: ，dxwaWB: journal，8x2mMQ: TY4X7V
ak9yM6	A7IHrH: 2001，sQJ/D8: ，sE9og+:， wzlKC/:

American Journal of PharmacoGenomics

uM3Gfz

sZFHBm

sZFHBm

sZFHBm

sZFHBm

Hi2Sc4

e7MLUV

XjnQ+b

Kq5Kd6

LB2xFn

XmiM++

A multilocus approach to the pharmacogenetics of thiazide diuretics

Genetic Risk Factors in Eating Disorders

A multilocus approach to the pharmacogenetics of thiazide diuretics

A multilocus approach to the pharmacogenetics of thiazide diuretics

Population Genomics of Drug Response

A multilocus approach to the pharmacogenetics of thiazide diuretics

A multilocus approach to the pharmacogenetics of thiazide diuretics

A multilocus approach to the pharmacogenetics of thiazide diuretics

A multilocus approach to the pharmacogenetics of thiazide diuretics

A multilocus approach to the pharmacogenetics of thiazide diuretics